Ibrutinib - capsule - 140 mg

DRUG2 trials

Sponsors

Janssen - Cilag International

Conditions

B-cell non-Hodgkin's lymphoma and cGVHDChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Phase 3

A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruitingCTIS2023-503469-49-00

Janssen - Cilag InternationalChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Start: 2018-04-19Target: 100Updated: 2025-12-08

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Active, not recruitingCTIS2023-503803-27-00

Janssen - Cilag InternationalB-cell non-Hodgkin's lymphoma and cGVHD

Start: 2013-10-25Target: 137Updated: 2026-01-27